11. Drugbank. Hydroxyprogesterone caproate. 2020. https://www.drugbank.ca/drugs/DB06789
12. FDA. Highlights of prescribing information MAKENA ® (Hydroxyprogesterone caproate injection) for intramuscular use. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021945s005lbl.pdf
16. Medscape. Hydroxyprogesterone Caproate. 2020. https://reference.medscape.com/drug/makena-hydroxyprogesterone-caproate-100076
17. Feghali M, Venkataramanan R, Caritis S. Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations. Seminars in Perinatology. 2014;38(8):516–22. doi:10.1053/j.semperi.2014.08.013.
18. Riccardo, A Casini ML, Loredana C, Mizar P, et al. Efficacy and safety of 17α-hydroxyprogesterone caproate in hormone replacement therapy. Gynecological Endocrinology. 2005;21(5):265–267. doi:10.1080/09513590500368650
19. Hines M, Lyseng-Williamson KA, Deeks ED. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth. Clinical Drug Investigation. 2013;33(3):223–7.
20. Hall NR. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?. Obstetrics and Gynecology Clinics of North America. 2011;38(2):235–46.